A novel longitudinal rank-sum test for multiple primary endpoints in clinical trials: Applications to neurodegenerative disorders

Neurodegenerative disorders such as Alzheimer’s disease (AD) present a significant global health challenge, characterized by cognitive decline, functional impairment, and other debilitating effects. Current AD clinical trials often assess multiple longitudinal primary endpoints to comprehensively evaluate treatment efficacy. Traditional methods, however, may fail to capture global treatment effects, require larger sample sizes due to multiplicity adjustments, and may not fully utilize the available longitudinal data. To address these limitations, we introduce the Longitudinal Rank Sum Test (LRST), a novel nonparametric rank-based omnibus test statistic. The LRST enables a comprehensive assessment of treatment efficacy across multiple endpoints and time points without the need for multiplicity adjustments, effectively controlling Type I error while enhancing statistical power. It offers flexibility for various data distributions encountered in AD research and maximizes the utilization of longitudinal data. Simulations across realistic clinical trial scenarios, including those with conflicting treatment effects, and real-data applications demonstrate the LRST’s performance, underscoring its potential as a valuable tool in AD clinical trials.